In-silico Design of Potent Anti-Tubercular Agents Containing Isatinylthiosemicarbazone Pharmacophore
Abstract
A recent study reveals that Isatinylthiosemicarbazone analogues inhibit mycobacterial growth by inhibiting the Isocitrate Lyase (ICL). Hence Two-dimensional (2D), Three-dimensional (3D), and Group QSAR (GQSAR) studies were performed to reduce the amount of pharmacophore needed to make effective ICL inhibitors. New Chemical Entities (NCEs) were created based on the findings of all QSAR studies. It was discovered that QSAR models produced noticeably positive statistical findings. i.e. (r2 > 0.7), cross-validation (q2 > 0.6), and external validation (pred_r2 > 0.6), indicating high predictability of all models. Utilizing molecular docking studies, the binding affinities of designed NCEs were investigated for the ICL enzyme (PDB code: 1F8M). The absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of designed NCEs were expected to have a pharmacokinetic profile similar to their drug. Overall, it is important to state that the methodology used for pharmacophore optimization using 2D, 3D, G-QSAR, and Molecular Docking ADMET research works was discovered to be extremely accurate.
Keywords:
Isatinylthiosemicarbazone, ICL inhibitor, QSAR, Docking, ADMET studyDOI
https://doi.org/10.25004/IJPSDR.2023.150606References
Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P. Global surveillance for antituberculosis-drug resistance, 1994–1997. N. Engl. J. Med. 1998; 338:1641-1649.
WHO Report, Global Tuberculosis Control Surveillance, Financing and Planning, 2021
Pepper DJ, Meintjes GA, McIlleron H, Wilkinson RJ. Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery. Drug Discovery Today. 2007; 12:980-989.
Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am. J. Respir. Crit. Care Med. 1998; 158:157-161.
Parrish NM, Dick JD, Bishai WR. Mechanisms of latency in Mycobacterium tuberculosis. Trends Microbiol. 1998; 6:107-112.
Sharma V, Sharma S, Zu Bentrup KH, McKinney JD, Russell DG, Jacobs WR, Sacchettini JC. Structure of isocitrate lyase, a persistence factor of Mycobacterium tuberculosis. Nat. Struct. Biol. 2000; 7:663-668.
Katz E. Thiosemicarbazones: inhibition of the growth of pox viruses and requirement for the growth of an isatin-β-thiosemicarbazone dependent mutant. J. Basic Clin. Physiol. Pharmacol. 1987; 6:119-30.
Cooper JA, Moss B, Katz E. Inhibition of vaccinia virus late protein synthesis by isatin-β-thiosemicarbazone: Characterization and in vitro translation of viral mRNA. Virology. 1979; 96:381-392.
Webber SE, Tikhe J, Worland ST, Fuhrman SA, Hendrickson TF, Matthews DA, Love RA, Patick AK, Meador JW, Ferre RA, Brown EL. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J. Med. Chem.1996; 39:5072-5082.
Ronen D, Sherman L, Bar-Nun S, Teitz Y. N-methylisatin-beta-4', 4'-diethylthiosemicarbazone, an inhibitor of Moloney leukemia virus protein production: characterization and in vitro translation of viral mRNA. Antimicrob. Agents Chemother. 1987; 31:1798-1802.
Chen LR, Wang YC, Lin YW, Chou SY, Chen SF, Liu LT, Wu YT, Kuo CJ, Chen TS, Juang SH. Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors. Bioorg. Med. Chem. Lett. 2005; 15:3058-3062.
Dudek AZ, Arodz T, Gálvez J. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb. Chem. High Throughput Screening. 2006; 9:213-228.
Tropsha A. Best practices for QSAR model development, validation, and exploitation. Mol. Inf. 2010; 29:476-88.
Banerjee D, Yogeeswari P, Bhat P, Thomas A, Srividya M, Sriram D. Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection. Eur. J. Med. Chem. 2011; 46:106-121.
Halgren TA. Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions. J. Comput. Chem. 1996; 17:520-552.
Topliss JG, Edwards RP. Chance factors in studies of quantitative structure-activity relationships. J. Med. Chem. 1979; 22:1238-1244.
Zheng W, Tropsha A. Novel variable selection quantitative structure− property relationship approach based on the k-nearest-neighbor principle. J. Chem. Inf. Comput. Sci. 2000; 40:185-194.
Shen M, Xiao Y, Golbraikh A, Gombar VK, Tropsha A. Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J. Med. Chem. 2003; 46: 3013-3020.
Ajmani S, Jadhav K, Kulkarni SA. Three-dimensional QSAR using the k-nearest neighbor method and its interpretation. J. Chem. Inf. Model. 2006; 46:24-31.
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2012; 64:4-17.
Published
Abstract Display: 404 
PDF Downloads: 369 
